HK1087122A1 - Novel farnesyl protein transferase inhibitors as antitumor agents - Google Patents

Novel farnesyl protein transferase inhibitors as antitumor agents

Info

Publication number
HK1087122A1
HK1087122A1 HK06107445.0A HK06107445A HK1087122A1 HK 1087122 A1 HK1087122 A1 HK 1087122A1 HK 06107445 A HK06107445 A HK 06107445A HK 1087122 A1 HK1087122 A1 HK 1087122A1
Authority
HK
Hong Kong
Prior art keywords
protein transferase
antitumor agents
transferase inhibitors
farnesyl protein
novel farnesyl
Prior art date
Application number
HK06107445.0A
Other languages
English (en)
Inventor
Hugh Y Zhu
Alan B Cooper
Jagdish A Desai
James J S Wang
Dinanath F Rane
Ronald J Doll
F George Njoroge
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1087122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1087122A1 publication Critical patent/HK1087122A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06107445.0A 2003-08-07 2006-06-30 Novel farnesyl protein transferase inhibitors as antitumor agents HK1087122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49326903P 2003-08-07 2003-08-07
US49850903P 2003-08-28 2003-08-28
PCT/US2004/025042 WO2005014577A1 (en) 2003-08-07 2004-08-04 Novel farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
HK1087122A1 true HK1087122A1 (en) 2006-10-06

Family

ID=34138747

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107445.0A HK1087122A1 (en) 2003-08-07 2006-06-30 Novel farnesyl protein transferase inhibitors as antitumor agents

Country Status (19)

Country Link
US (1) US7557107B2 (es)
EP (1) EP1660477B1 (es)
JP (1) JP2007501791A (es)
KR (1) KR20060057599A (es)
AR (1) AR045447A1 (es)
AT (1) ATE417041T1 (es)
AU (1) AU2004263493A1 (es)
BR (1) BRPI0413384A (es)
CA (1) CA2535210A1 (es)
DE (1) DE602004018332D1 (es)
EC (1) ECSP066349A (es)
ES (1) ES2317047T3 (es)
HK (1) HK1087122A1 (es)
IL (1) IL173514A0 (es)
MX (1) MXPA06001483A (es)
PE (1) PE20050336A1 (es)
RU (1) RU2006106768A (es)
TW (1) TW200510384A (es)
WO (1) WO2005014577A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CA2591705A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
CN101198314A (zh) * 2005-04-12 2008-06-11 伊兰制药国际有限公司 纳米微粒喹唑啉衍生物制剂
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
US20070213340A1 (en) * 2006-01-19 2007-09-13 Kelly Joseph M Farnesyl protein transferase inhibitors
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL125062A (en) 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
WO2001064199A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
US20030229099A1 (en) * 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CN1849122A (zh) 2001-12-03 2006-10-18 先灵公司 Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
CA2591705A1 (en) 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents

Also Published As

Publication number Publication date
MXPA06001483A (es) 2006-05-15
US20050059672A1 (en) 2005-03-17
DE602004018332D1 (de) 2009-01-22
WO2005014577A1 (en) 2005-02-17
EP1660477A1 (en) 2006-05-31
WO2005014577A9 (en) 2006-03-23
EP1660477B1 (en) 2008-12-10
ECSP066349A (es) 2006-08-30
ATE417041T1 (de) 2008-12-15
PE20050336A1 (es) 2005-05-30
JP2007501791A (ja) 2007-02-01
US7557107B2 (en) 2009-07-07
RU2006106768A (ru) 2007-09-20
TW200510384A (en) 2005-03-16
ES2317047T3 (es) 2009-04-16
AU2004263493A1 (en) 2005-02-17
KR20060057599A (ko) 2006-05-26
IL173514A0 (en) 2006-07-05
AR045447A1 (es) 2005-10-26
CA2535210A1 (en) 2005-02-17
BRPI0413384A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
IL173514A0 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL208520A0 (en) Akt protein kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
EP1673343A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
EP1613595A4 (en) NOVEL COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE
EP1670771A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
IL163673A0 (en) Farnesyl protein transferase inhibitors as antitumor agents
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
EP1658290A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ATE359281T1 (de) Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren
EP1670780A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ZA200705126B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
GB0311195D0 (en) Glyoxalase inhibitors
IL155668A0 (en) Novel farnesyl protein transferase inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
PL379168A1 (pl) Pochodne kaptoprilu
EP1598335A4 (en) PROSTAGLANDINE DERIVATIVES
GB0312619D0 (en) Complement inhibitors
GB0329869D0 (en) Inhibitors
GB0300607D0 (en) Inhibitors
GB0311194D0 (en) Glyoxalase i inhibitors
GB0327386D0 (en) Complement inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120804